A pilot study of Elaspol (Sivelestat Sodium) for neuromyelitis optica - A pilot study of Elaspol (Sivelestat Sodium) for neuromyelitis optica

Tohoku University Hospital0 个研究点目标入组 10 人开始时间: 2013年4月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Patients with multiple sclerosis. 2) Patients with severe cardiac disease, severe liver disease, severe lung disease, severe gastrointestinal disease, severe kidney disease, immunodeficiency disease, or other diseases which organizer consider to be inappropriate. 3) Patients who have more than four organs dysfunction. 4) Patients who have or had asthma which requires continuous treatment. 5) Patients who have or had malignant diseases. 6) Patients who have severe autoimmune inflammatory diseases. 7) Patients with systemic infection including bacterial, viral, fungal, HBV, HCV, and HIV. 8) Patients who can not assess by MRI with gadolinium enhancement. 9) Patients who have received treatments listed below after the relapse. a. steroid pulse therapy b. plasmapheresis 10) Patients with increased serum transaminase levels. AST: higher than 5 times reference range ALT: higher than 5 times reference range 11) Patients with alcoholism. 12) Patients who had entered other clinical trials within 3 months. 13) Patients with pregnancy. 14) Patients with breastfeeding. 15) Patients who have severe allergic reactions. 16) Patients who can't cooperate with medical stuff.

发起方